Zogenix (ZGNX) reported quarterly earnings results on Tuesday, May-10-2016. The company said it had a profit of $-0.42 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.20. Analysts had a consensus of $-0.62. The company posted revenue of $9.20 million in the period, compared to analysts expectations of $5.88 million. The company’s revenue was up 100.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.19 EPS.
Zogenix closed down -0.03 points or -0.32% at $9.45 with 1,62,042 shares getting traded on Friday. Post opening the session at $9.35, the shares hit an intraday low of $9.12 and an intraday high of $9.65 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Dec 18, 2015, Roger Hawley (director) purchased 10,000 shares at $13.74 per share price. According to the SEC, on Dec 8, 2015, Renee P Tannenbaum (director) purchased 5,000 shares at $15.40 per share price.
Zogenix Inc. (Zogenix) is a pharmaceutical company which is engaged in development and commercialization of therapies for people with central nervous system (CNS) disorders. The Company focuses on the areas of pain epilepsy and schizophrenia. It is engaged in the development of Relday a product candidate for the treatment of schizophrenia. The Company develops ZX007 an abuse-deterrent tablet formulation of single entity extended-release hydrocodone. The Company commercializes Sumavel DosePro (sumatriptan injection) a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache. The Company sells Sumavel DosePro to wholesale pharmaceutical distributors pharmacies and hospitals.